A Comparison of Intra-Articular Hyaluronic Acid Competitors in the Treatment of Mild to Moderate Knee Osteoarthritis
Full list of Authors
McGrath AF, McGrath AM, Jessop ZM, Gandham S, Datta G, Dawson-Bowling S, Cannon SR.
Full AMA reference
McGrath A., McGrath AM., Jessop ZM., et al. A Comparison of Intra-Articular Hyaluronic Acid Competitors in the Treatment of Mild to Moderate Knee Osteoarthritis. J Arthritis. 2013.
Objective
To compare the efficacy and complications of two single injection HA treatments for knee OA (Synvisc-One® and DUROLANE).
Conclusion
McGrath et al. treated 182 knees with KL-II and KL-III grade osteoarthritis. Patients were followed up at 3, 6, 9 and 12 months. Significant improvement is seen in the VAS, SF 36 V2 and Oxford Knee Scores (p=0.01). At 6 months, this difference is extended in the DUROLANE group (p=0.0001) compared to Synvisc® (P=0.783). The abstract states AEs occurred significantly less with DUROLANE’ but the only mention of this in the text is that 9 patients suffered an AE. Results suggest that HA treatment for mild to moderate OA can provide pain relief for up to six months along with reducing the need for analgesic and anti-inflammatory medication.
